冠心病患者介入治疗后氯吡格雷不同疗程对血清白介素-18和C-反应蛋白的影响

The effects of clopidogrel on inflammatory cytokines in patients with coronary heart disease（CHD） after percutaneous coronary intervention（PCI）

目的评价冠状动脉介入治疗（PCI）后，氯吡格雷不同疗程对血清白细胞介素-18和C-反应蛋白的影响。方法将68例PCI的冠心病患者随机分为氯吡格雷治疗1个月组（A组）34例、氯吡格雷治疗6个月组（B组）34例，观察治疗前、后血清白细胞介素-18（IL-18）和C-反应蛋白（hs-CRP）浓度。结果治疗后B组IL-18和hs—CRP降低更为显著。与A组差异有统计学意义（P〈0．05）。结论氯毗格雷可在常规治疗基础上显著降低冠心病患者PCI术后炎性因子浓度。

Objective To observe the effects of elopidogrel on inflammatory eytokines in patients with coronary heart disease （CHD） after pereutaneous coronary intervention （PCI）. Methods 68 eases diagnosed of CHD were randomly divided into elopidogrel I month group（ group A）, elopidogrel 6 months（ roup B）, every group had 34 eases. Before and after treatment adopt fasting blood respectively and in determination of serum intefleukin-18 （IL-18） and C-reactive protein（hs-CRP）. Results IL-18 and CRP were reduced more apparently in group B. Compared with group A,there were significant differences （P 〈 0.05 ）. Conclusion Clopidogrel could significantly reduce coronary heart disease patients in which based on conventional treatment postoperative PCI inflammatory reaction, reduce the patients with coronary artery disease postoperative PCI vascular inflammatory reaction.